The global peptide therapeutics CDMO market is witnessing strong growth as pharma and biotech firms outsource peptide drug manufacturing. CDMOs offer expertise in synthesis, purification, and compliance for complex molecules. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Peptide Therapeutics CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Peptide Therapeutics CDMO Market, by Synthesis Method
8.1.1. Solid-Phase Peptide Synthesis (SPPS)
8.1.1.1. Market Revenue and Forecast
8.1.2. Liquid-Phase Peptide Synthesis (LPPS)
8.1.2.1. Market Revenue and Forecast
8.1.3. Hybrid/Mixed-Phase Synthesis
8.1.3.1. Market Revenue and Forecast
8.1.4. Recombinant Peptide Production
8.1.4.1. Market Revenue and Forecast
8.1.5. Chemical Synthesis Methods
8.1.5.1. Market Revenue and Forecast
8.1.6. Enzymatic Synthesis Approaches
8.1.6.1. Market Revenue and Forecast
8.1.7. Fragment Condensation Techniques
8.1.7.1. Market Revenue and Forecast
8.1.8. Convergent Synthesis Strategies
8.1.8.1. Market Revenue and Forecast
9.1. Peptide Therapeutics CDMO Market, by Service Type
9.1.1. API Development & Manufacturing
9.1.1.1. Market Revenue and Forecast
9.1.2. Process Development & Optimization
9.1.2.1. Market Revenue and Forecast
9.1.3. Analytical Method Development & Validation
9.1.3.1. Market Revenue and Forecast
9.1.4. Regulatory Affairs & CMC Support
9.1.4.1. Market Revenue and Forecast
9.1.5. Formulation Development
9.1.5.1. Market Revenue and Forecast
9.1.6. Fill-Finish & Packaging Services
9.1.6.1. Market Revenue and Forecast
9.1.7. Quality Control & Assurance
9.1.7.1. Market Revenue and Forecast
9.1.8. Clinical Trial Material Manufacturing
9.1.8.1. Market Revenue and Forecast
9.1.9. Commercial Manufacturing
9.1.9.1. Market Revenue and Forecast
9.1.10. Technology Transfer Services
9.1.10.1. Market Revenue and Forecast
10.1. Peptide Therapeutics CDMO Market, by Peptide Type
10.1.1. Generic Peptides
10.1.1.1. Market Revenue and Forecast
10.1.2. Innovative/Novel Peptides
10.1.2.1. Market Revenue and Forecast
10.1.3. Modified Peptides (PEGylated, Lipidated)
10.1.3.1. Market Revenue and Forecast
10.1.4. Cyclic Peptides
10.1.4.1. Market Revenue and Forecast
10.1.5. Stapled Peptides
10.1.5.1. Market Revenue and Forecast
10.1.6. Peptide-Drug Conjugates (PDCs)
10.1.6.1. Market Revenue and Forecast
10.1.7. Antimicrobial Peptides
10.1.7.1. Market Revenue and Forecast
10.1.8. Hormonal Peptides
10.1.8.1. Market Revenue and Forecast
10.1.9. Therapeutic Proteins & Peptides
10.1.9.1. Market Revenue and Forecast
10.1.10. Cosmetic & Nutraceutical Peptides
10.1.10.1. Market Revenue and Forecast
11.1. Peptide Therapeutics CDMO Market, by Application Area
11.1.1. Oncology & Cancer Treatment
11.1.1.1. Market Revenue and Forecast
11.1.2. Diabetes & Metabolic Disorders
11.1.2.1. Market Revenue and Forecast
11.1.3. Cardiovascular Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. Central Nervous System Disorders
11.1.4.1. Market Revenue and Forecast
11.1.5. Infectious Diseases
11.1.5.1. Market Revenue and Forecast
11.1.6. Autoimmune & Inflammatory Conditions
11.1.6.1. Market Revenue and Forecast
11.1.7. Hormonal Therapies
11.1.7.1. Market Revenue and Forecast
11.1.8. Pain Management
11.1.8.1. Market Revenue and Forecast
11.1.9. Dermatology & Cosmetics
11.1.9.1. Market Revenue and Forecast
11.1.10. Gastrointestinal Disorders
11.1.10.1. Market Revenue and Forecast
12.1. Peptide Therapeutics CDMO Market, by Scale of Operation
12.1.1. Research & Development Scale
12.1.1.1. Market Revenue and Forecast
12.1.2. Clinical Trial Manufacturing
12.1.2.1. Market Revenue and Forecast
12.1.3. Pilot Scale Production
12.1.3.1. Market Revenue and Forecast
12.1.4. Commercial Scale Manufacturing
12.1.4.1. Market Revenue and Forecast
12.1.5. Large-Scale Industrial Production
12.1.5.1. Market Revenue and Forecast
13.1. Peptide Therapeutics CDMO Market, by End-User Type
13.1.1. Large Pharmaceutical Companies
13.1.1.1. Market Revenue and Forecast
13.1.2. Biotechnology Companies
13.1.2.1. Market Revenue and Forecast
13.1.3. Academic & Research Institutions
13.1.3.1. Market Revenue and Forecast
13.1.4. Government Research Organizations
13.1.4.1. Market Revenue and Forecast
13.1.5. Clinical Research Organizations (CROs)
13.1.5.1. Market Revenue and Forecast
13.1.6. Specialty Pharmaceutical Companies
13.1.6.1. Market Revenue and Forecast
13.1.7. Generic Drug Manufacturers
13.1.7.1. Market Revenue and Forecast
13.1.8. Cosmetic & Nutraceutical Companies
13.1.8.1. Market Revenue and Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Synthesis Method
14.1.2. Market Revenue and Forecast, by Service Type
14.1.3. Market Revenue and Forecast, by Peptide Type
14.1.4. Market Revenue and Forecast, by Application Area
14.1.5. Market Revenue and Forecast, by Scale of Operation
14.1.6. Market Revenue and Forecast, by End-User Type
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Synthesis Method
14.1.7.2. Market Revenue and Forecast, by Service Type
14.1.7.3. Market Revenue and Forecast, by Peptide Type
14.1.7.4. Market Revenue and Forecast, by Application Area
14.1.8. Market Revenue and Forecast, by Scale of Operation
14.1.8.1. Market Revenue and Forecast, by End-User Type
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Synthesis Method
14.1.9.2. Market Revenue and Forecast, by Service Type
14.1.9.3. Market Revenue and Forecast, by Peptide Type
14.1.9.4. Market Revenue and Forecast, by Application Area
14.1.10. Market Revenue and Forecast, by Scale of Operation
14.1.11. Market Revenue and Forecast, by End-User Type
14.2. Europe
14.2.1. Market Revenue and Forecast, by Synthesis Method
14.2.2. Market Revenue and Forecast, by Service Type
14.2.3. Market Revenue and Forecast, by Peptide Type
14.2.4. Market Revenue and Forecast, by Application Area
14.2.5. Market Revenue and Forecast, by Scale of Operation
14.2.6. Market Revenue and Forecast, by End-User Type
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Synthesis Method
14.2.8.2. Market Revenue and Forecast, by Service Type
14.2.8.3. Market Revenue and Forecast, by Peptide Type
14.2.9. Market Revenue and Forecast, by Application Area
14.2.10. Market Revenue and Forecast, by Scale of Operation
14.2.10.1. Market Revenue and Forecast, by End-User Type
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Synthesis Method
14.2.11.2. Market Revenue and Forecast, by Service Type
14.2.11.3. Market Revenue and Forecast, by Peptide Type
14.2.12. Market Revenue and Forecast, by Application Area
14.2.13. Market Revenue and Forecast, by Scale of Operation
14.2.14. Market Revenue and Forecast, by End-User Type
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Synthesis Method
14.2.15.2. Market Revenue and Forecast, by Service Type
14.2.15.3. Market Revenue and Forecast, by Peptide Type
14.2.15.4. Market Revenue and Forecast, by Application Area
14.2.16. Market Revenue and Forecast, by Scale of Operation
14.2.16.1. Market Revenue and Forecast, by End-User Type
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Synthesis Method
14.2.17.2. Market Revenue and Forecast, by Service Type
14.2.17.3. Market Revenue and Forecast, by Peptide Type
14.2.17.4. Market Revenue and Forecast, by Application Area
14.2.18. Market Revenue and Forecast, by Scale of Operation
14.2.18.1. Market Revenue and Forecast, by End-User Type
14.3. APAC
14.3.1. Market Revenue and Forecast, by Synthesis Method
14.3.2. Market Revenue and Forecast, by Service Type
14.3.3. Market Revenue and Forecast, by Peptide Type
14.3.4. Market Revenue and Forecast, by Application Area
14.3.5. Market Revenue and Forecast, by Scale of Operation
14.3.6. Market Revenue and Forecast, by End-User Type
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Synthesis Method
14.3.7.2. Market Revenue and Forecast, by Service Type
14.3.7.3. Market Revenue and Forecast, by Peptide Type
14.3.7.4. Market Revenue and Forecast, by Application Area
14.3.8. Market Revenue and Forecast, by Scale of Operation
14.3.9. Market Revenue and Forecast, by End-User Type
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Synthesis Method
14.3.10.2. Market Revenue and Forecast, by Service Type
14.3.10.3. Market Revenue and Forecast, by Peptide Type
14.3.10.4. Market Revenue and Forecast, by Application Area
14.3.11. Market Revenue and Forecast, by Scale of Operation
14.3.11.1. Market Revenue and Forecast, by End-User Type
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Synthesis Method
14.3.12.2. Market Revenue and Forecast, by Service Type
14.3.12.3. Market Revenue and Forecast, by Peptide Type
14.3.12.4. Market Revenue and Forecast, by Application Area
14.3.12.5. Market Revenue and Forecast, by Scale of Operation
14.3.12.6. Market Revenue and Forecast, by End-User Type
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Synthesis Method
14.3.13.2. Market Revenue and Forecast, by Service Type
14.3.13.3. Market Revenue and Forecast, by Peptide Type
14.3.13.4. Market Revenue and Forecast, by Application Area
14.3.13.5. Market Revenue and Forecast, by Scale of Operation
14.3.13.6. Market Revenue and Forecast, by End-User Type
14.4. MEA
14.4.1. Market Revenue and Forecast, by Synthesis Method
14.4.2. Market Revenue and Forecast, by Service Type
14.4.3. Market Revenue and Forecast, by Peptide Type
14.4.4. Market Revenue and Forecast, by Application Area
14.4.5. Market Revenue and Forecast, by Scale of Operation
14.4.6. Market Revenue and Forecast, by End-User Type
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Synthesis Method
14.4.7.2. Market Revenue and Forecast, by Service Type
14.4.7.3. Market Revenue and Forecast, by Peptide Type
14.4.7.4. Market Revenue and Forecast, by Application Area
14.4.8. Market Revenue and Forecast, by Scale of Operation
14.4.9. Market Revenue and Forecast, by End-User Type
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Synthesis Method
14.4.10.2. Market Revenue and Forecast, by Service Type
14.4.10.3. Market Revenue and Forecast, by Peptide Type
14.4.10.4. Market Revenue and Forecast, by Application Area
14.4.11. Market Revenue and Forecast, by Scale of Operation
14.4.12. Market Revenue and Forecast, by End-User Type
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Synthesis Method
14.4.13.2. Market Revenue and Forecast, by Service Type
14.4.13.3. Market Revenue and Forecast, by Peptide Type
14.4.13.4. Market Revenue and Forecast, by Application Area
14.4.13.5. Market Revenue and Forecast, by Scale of Operation
14.4.13.6. Market Revenue and Forecast, by End-User Type
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Synthesis Method
14.4.14.2. Market Revenue and Forecast, by Service Type
14.4.14.3. Market Revenue and Forecast, by Peptide Type
14.4.14.4. Market Revenue and Forecast, by Application Area
14.4.14.5. Market Revenue and Forecast, by Scale of Operation
14.4.14.6. Market Revenue and Forecast, by End-User Type
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Synthesis Method
14.5.2. Market Revenue and Forecast, by Service Type
14.5.3. Market Revenue and Forecast, by Peptide Type
14.5.4. Market Revenue and Forecast, by Application Area
14.5.5. Market Revenue and Forecast, by Scale of Operation
14.5.6. Market Revenue and Forecast, by End-User Type
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Synthesis Method
14.5.7.2. Market Revenue and Forecast, by Service Type
14.5.7.3. Market Revenue and Forecast, by Peptide Type
14.5.7.4. Market Revenue and Forecast, by Application Area
14.5.8. Market Revenue and Forecast, by Scale of Operation
14.5.8.1. Market Revenue and Forecast, by End-User Type
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Synthesis Method
14.5.9.2. Market Revenue and Forecast, by Service Type
14.5.9.3. Market Revenue and Forecast, by Peptide Type
14.5.9.4. Market Revenue and Forecast, by Application Area
14.5.9.5. Market Revenue and Forecast, by Scale of Operation
14.5.9.6. Market Revenue and Forecast, by End-User Type
15.1. Almac Group
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. AmbioPharm Inc.
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. American Peptide Company
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Auspep Pty Ltd.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Bachem AG
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. BCN Peptides S.A.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Chinese Peptide Company (CPC)
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. CordenPharma International
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. CPC Scientific Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Creative Peptides
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description